Mizuho raised the firm’s price target on LeonaBio (LONA) to $16 from $10 and keeps an Outperform rating on the shares post the Q4 report. The firm views LeonaBio as a “below-the-radar” and “underappreciated” name. The analyst increased its peak sales estimates for lasofoxifene after analyzing the competitive landscape and the breast cancer opportunity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LONA:
- Leonabio Warns of Major Financial and Operational Risks in Lasofoxifene Program Integration
- LeonaBio Updates Investors on 2025 Results and Strategy
- LeonaBio Expands Share Authorization to Support Future Financing
- Is ATHA a Buy, Before Earnings?
- LeonaBio initiated with an Overweight at Cantor Fitzgerald